Kevin Neil

Company: TATUM Bioscience

Job title: Chief Scientific Officer and Co-Founder

Seminars:

Leveraging Engineered Bacteriophages to Target Cancer Cells & Induce an Immune Response Against Tumors 2:30 pm

Utilizing non-lytic filamentous bacteriophages for their shape and ease of purification as the basis for immunotherapy Developing the nanofilament TAT003 as an immunotherapy injected directly to the tumor and stick to cancer cells, reshape the surface and activate the immune system Fusing cancer protein genes and therapeutic genes to the bacteriophage to achieve antitumor response…Read more

day: Conference Day One